Round Hill Asset Management held its stake in shares of Novo Nordisk A/S (NYSE:NVO) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 52,460 shares of the company’s stock at the close of the second quarter. Novo Nordisk A/S comprises approximately 1.3% of Round Hill Asset Management’s holdings, making the stock its 19th largest position. Round Hill Asset Management’s holdings in Novo Nordisk A/S were worth $2,250,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also modified their holdings of NVO. State Street Corp raised its stake in Novo Nordisk A/S by 64,406.4% during the first quarter. State Street Corp now owns 5,593,351 shares of the company’s stock worth $191,740,000 after acquiring an additional 5,584,680 shares in the last quarter. Renaissance Technologies LLC raised its stake in Novo Nordisk A/S by 17.7% during the first quarter. Renaissance Technologies LLC now owns 16,409,200 shares of the company’s stock worth $562,507,000 after acquiring an additional 2,463,300 shares in the last quarter. Fisher Asset Management LLC raised its stake in Novo Nordisk A/S by 12.9% during the second quarter. Fisher Asset Management LLC now owns 11,690,997 shares of the company’s stock worth $501,427,000 after acquiring an additional 1,331,992 shares in the last quarter. Folketrygdfondet raised its stake in Novo Nordisk A/S by 13.2% during the second quarter. Folketrygdfondet now owns 6,914,192 shares of the company’s stock worth $296,550,000 after acquiring an additional 803,608 shares in the last quarter. Finally, Sustainable Growth Advisers LP raised its stake in Novo Nordisk A/S by 17.3% during the first quarter. Sustainable Growth Advisers LP now owns 4,068,896 shares of the company’s stock worth $139,482,000 after acquiring an additional 598,644 shares in the last quarter. 6.01% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: “Novo Nordisk A/S (NVO) Position Held by Round Hill Asset Management” was first posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://www.chaffeybreeze.com/2017/09/15/novo-nordisk-as-nvo-position-held-by-round-hill-asset-management.html.
Several analysts have recently weighed in on NVO shares. BidaskClub upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Thursday, June 15th. Zacks Investment Research upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating and set a $49.00 price target on the stock in a report on Wednesday, June 21st. Finally, Bank of America Corporation upgraded Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a report on Wednesday, September 6th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $56.00.
Novo Nordisk A/S (NVO) traded down 0.76% during mid-day trading on Friday, hitting $48.28. The stock had a trading volume of 1,213,114 shares. Novo Nordisk A/S has a 52 week low of $30.89 and a 52 week high of $48.88. The firm has a market cap of $119.74 billion, a PE ratio of 19.51 and a beta of 0.60. The company’s 50 day moving average price is $45.42 and its 200 day moving average price is $40.76.
The company also recently disclosed an annual dividend, which was paid on Tuesday, August 29th. Investors of record on Monday, August 21st were issued a dividend of $0.336 per share. This represents a dividend yield of 1.07%. This is a boost from Novo Nordisk A/S’s previous annual dividend of $0.33. The ex-dividend date of this dividend was Friday, August 18th. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 36.44%.
About Novo Nordisk A/S
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.